Thomas Dee and Brian Kaspar, PhD, two proven experts in bringing gene therapy treatments successfully to market, have increased their roles on ENDSULIN’s Board of Directors as the company continues to make progress towards its goal of freeing millions of diabetic patients from the cumbersome daily treatment of their disease.
Dee, previous Chief Finance Officer of blockbuster gene therapy company AveXis, has been elected as Chair of Endsulin’s Board of Directors. As financial lead for one of only two successful commercial gene therapy companies to date, Dee is among a small handful of industry pioneers who have successfully led this type of venture all the way from start-up to market. Dee has served on Endsulin’s Board of Directors since October of 2020. Previously, he served as SVP and CFO at AveXis following a 20+ year career at Abbott Laboratories.
Dr. Kaspar joins Endsulin’s Board of Directors after previously serving on the company’s Scientific Advisory Board since January 2021. A founder of two gene therapy-based biotech companies, Kaspar served as Founding Chief Science Officer at AveXis, which developed Zolgensma, a gene therapy for Spinal Muscular Atrophy. He was formerly Principal Investigator at the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital.
Founded by world-leading transplant surgeon and gene-therapy researcher Dr. Hans Sollinger, ENDSULIN has assembled a powerhouse of experts across diabetes research, gene therapy and therapeutic commercialization who are focused on guiding the company through the pre-clinical and clinical development stages.
